Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Diagnostic Biomarkers Market by Product Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers), by Application (Drug Discovery and Development, Diagnostic, Disease Risk Assessment, Personalized Medicine, Others) and by End User (Hospitals, Cancer Research Institutes, Diagnostic Labs): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13936

Pages: NA

Charts: NA

Tables: NA

Biomarkers are used for various purposes such as disease diagnosis, prognosis, prediction, and assessment of treatment response. Diagnostic biomarkers have early inferences for the detection of patent ductus arteriosus (PDA). Predictive markers provide personalized treatment regimens and prognostic markers predict patient survival and recurrence patterns.

Biomarkers are used for clinical diagnostics for detecting multiple diseases, for instance, creatinine for diagnosing renal insufficiency, troponin level for diagnosing myocardial infarction, and amylase for pancreatitis. Biomarkers provide an approach in understanding the dynamics of neurological disease with the contribution in applications of analytical epidemiology and clinical trials. Diagnostic biomarkers can extend the base of information of the underlying pathology of disease along with providing means for homogeneous classification of a disease's possible factors that are a risk for the body.

COVID-19 Impact analysis

  • As the number of COVID-19 cases and deaths continue to rise steadily worldwide, the common goal of scientists, healthcare providers, and government officials worldwide has been to find the best way to detect and treat the viral infection of the COVID-19 virus.
  • Precise detection, effective treatment, timely diagnosis, and future prevention are the vital keys to the management of COVID-19, and can help curb the viral spread. Traditionally, biomarkers play a crucial role in the early detection of disease etiology, diagnosis, and treatment. Therefore, COVID-19 has a positive impact on the diagnostic biomarkers market.

Top Impacting Factors
High prevalence of cancer and other chronic disorders is the key driver for market growth.
Increasing diagnostic applications of biomarkers and rising R&D funding for pharma and biotech companies are few factors responsible for propelling the diagnostic biomarkers market growth. 
Moreover, low cost of clinical trials in developing countries and new initiatives for research contribute toward the growth of the global diagnostic biomarkers market. 
Biomarkers are prominently used in application areas such as personalized medicines, companion diagnostics, and other diagnostic areas, including drug discovery & development and disease risk assessment. These increasing diagnostic applications of biomarkers are expected to drive market growth in the forecasted years. 
Advancements in laboratory techniques and expansion of the molecular biology sector are other key factors stimulating the growth of the diagnostic biomarker market.
On the other hand, poorly suited regulatory and reimbursement systems, high capital investments, low cost-benefit ratio, and technical issues related to sample collection & storage are the major factors restraining the growth of this market.

Market Trends
New product launches to flourish the market

  • On August 27, 2020, a U.S.-based software company, Translational Imaging Innovations Inc., which is fast-tracking the development of diagnostic biomarkers of eye disease via its novel image management & analytics software, announced that it had been awarded an SBIR (Small Business Innovation Research) award, worth USD 1.5 million by the National Eye Institute of the NIH. 
  • On August 5, 2020, an Israeli start-up, Sight Diagnostics, developing a machine-vision-based finger-prick analysis device, announced that it had raised USD 71 million in Series D funding. The company suggests that its platform may offer a significant role in the early detection of conditions such as cancer, sepsis, and is currently investigated for potential use in monitoring biomarkers tied to the coronavirus severity.

Surge in usage due to cancer

  • Owing to the growing prevalence of cancer worldwide, the use of cancer biomarkers has increased significantly in recent years, providing opportunities for improving the management of cancer patients by enhancing detection and efficacy of treatment. Cancer biomarkers are present in tumor tissues or sera and encompass a wide variety of molecules, including mRNA, DNA, transcription factors, cell surface receptors, and secreted proteins. These biomarkers can be used for the prognosis and predicting the natural course of a tumor. They can further help doctors decide which patients are likely to respond to a given drug (prediction) and at what dosage it might be most effective (pharmacodynamics).

Key Benefits of the Report

  • This study presents the analytical depiction of the diagnostic biomarkers along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the diagnostic biomarkers market share.
  • The current market is quantitatively analyzed to highlight the diagnostic biomarkers market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed diagnostic biomarkers market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Diagnostic Biomarkers Report

  • Who are the leading market players active in the diagnostic biomarkers market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What future projections would help in taking further strategic steps?
  • What is "diagnostic biomarkers "?
  • What is "diagnostic biomarkers " market prediction in the future?
  • Who are the leading global players in the "diagnostic biomarkers " market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "diagnostic biomarkers " market report?

 Key Market Segments

  • By Product Type
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Validation Biomarkers
  • By Application
    • Drug Discovery and Development
    • Diagnostic
    • Disease Risk Assessment
    • Personalized Medicine
    • Others
  • By End User
    • Hospitals
    • Cancer Research Institutes
    • Diagnostic Labs
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

 
Key Market Players

  • Biosims Technologies Sas
  • Perkinelmer, Inc.
  • Biomedical Corp.
  • Merck Millipore
  • Banyan Biomarkers, Inc,
  • Qiagen N.V.
  • Signosis, Inc
  • EKF Diagnostics Holdings, Inc.
  • Cisbio Bioassays
  • Meso Scale Diagnostics, LLC.
  • Enzo Biochem, Inc.
  • Bio-Rad Laboratories, Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: DIAGNOSTIC BIOMARKERS MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Safety Biomarkers

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Efficacy Biomarkers

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Validation Biomarkers

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: DIAGNOSTIC BIOMARKERS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Drug Discovery And Development

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Diagnostic

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Disease Risk Assessment

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Personalized Medicine

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: DIAGNOSTIC BIOMARKERS MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Cancer Research Institutes

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Diagnostic Labs

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: DIAGNOSTIC BIOMARKERS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product Type

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Diagnostic Biomarkers Market

        • 7.2.6.1. Market Size and Forecast, By Product Type
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End User

      • 7.2.7. Canada Diagnostic Biomarkers Market

        • 7.2.7.1. Market Size and Forecast, By Product Type
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End User

      • 7.2.8. Mexico Diagnostic Biomarkers Market

        • 7.2.8.1. Market Size and Forecast, By Product Type
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End User

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product Type

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Diagnostic Biomarkers Market

        • 7.3.6.1. Market Size and Forecast, By Product Type
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End User

      • 7.3.7. Germany Diagnostic Biomarkers Market

        • 7.3.7.1. Market Size and Forecast, By Product Type
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End User

      • 7.3.8. Italy Diagnostic Biomarkers Market

        • 7.3.8.1. Market Size and Forecast, By Product Type
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End User

      • 7.3.9. Spain Diagnostic Biomarkers Market

        • 7.3.9.1. Market Size and Forecast, By Product Type
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End User

      • 7.3.10. UK Diagnostic Biomarkers Market

        • 7.3.10.1. Market Size and Forecast, By Product Type
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End User

      • 7.3.11. Russia Diagnostic Biomarkers Market

        • 7.3.11.1. Market Size and Forecast, By Product Type
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End User

      • 7.3.12. Rest Of Europe Diagnostic Biomarkers Market

        • 7.3.12.1. Market Size and Forecast, By Product Type
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product Type

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Diagnostic Biomarkers Market

        • 7.4.6.1. Market Size and Forecast, By Product Type
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End User

      • 7.4.7. Japan Diagnostic Biomarkers Market

        • 7.4.7.1. Market Size and Forecast, By Product Type
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End User

      • 7.4.8. India Diagnostic Biomarkers Market

        • 7.4.8.1. Market Size and Forecast, By Product Type
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End User

      • 7.4.9. South Korea Diagnostic Biomarkers Market

        • 7.4.9.1. Market Size and Forecast, By Product Type
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End User

      • 7.4.10. Australia Diagnostic Biomarkers Market

        • 7.4.10.1. Market Size and Forecast, By Product Type
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End User

      • 7.4.11. Thailand Diagnostic Biomarkers Market

        • 7.4.11.1. Market Size and Forecast, By Product Type
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End User

      • 7.4.12. Malaysia Diagnostic Biomarkers Market

        • 7.4.12.1. Market Size and Forecast, By Product Type
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End User

      • 7.4.13. Indonesia Diagnostic Biomarkers Market

        • 7.4.13.1. Market Size and Forecast, By Product Type
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End User

      • 7.4.14. Rest of Asia Pacific Diagnostic Biomarkers Market

        • 7.4.14.1. Market Size and Forecast, By Product Type
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End User

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product Type

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Diagnostic Biomarkers Market

        • 7.5.6.1. Market Size and Forecast, By Product Type
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End User

      • 7.5.7. South Africa Diagnostic Biomarkers Market

        • 7.5.7.1. Market Size and Forecast, By Product Type
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End User

      • 7.5.8. Saudi Arabia Diagnostic Biomarkers Market

        • 7.5.8.1. Market Size and Forecast, By Product Type
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End User

      • 7.5.9. UAE Diagnostic Biomarkers Market

        • 7.5.9.1. Market Size and Forecast, By Product Type
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End User

      • 7.5.10. Argentina Diagnostic Biomarkers Market

        • 7.5.10.1. Market Size and Forecast, By Product Type
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End User

      • 7.5.11. Rest of LAMEA Diagnostic Biomarkers Market

        • 7.5.11.1. Market Size and Forecast, By Product Type
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Qiagen N.V.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Perkinelmer, Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Merck Millipore

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Bio-Rad Laboratories, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Enzo Biochem, Inc.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. EKF Diagnostics Holdings, Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Meso Scale Diagnostics, LLC.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Biosims Technologies Sas

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Cisbio Bioassays

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Signosis, Inc

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Banyan Biomarkers, Inc,

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

    • 9.12. Biomedical Corp.

      • 9.12.1. Company Overview

      • 9.12.2. Key Executives

      • 9.12.3. Company Snapshot

      • 9.12.4. Operating Business Segments

      • 9.12.5. Product Portfolio

      • 9.12.6. Business Performance

      • 9.12.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL DIAGNOSTIC BIOMARKERS MARKET, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC BIOMARKERS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR DIAGNOSTIC, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC BIOMARKERS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR CANCER RESEARCH INSTITUTES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC BIOMARKERS MARKET FOR DIAGNOSTIC LABS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC BIOMARKERS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA DIAGNOSTIC BIOMARKERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 20. U.S. DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 21. U.S. DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. U.S. DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 23. CANADA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 24. CANADA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. CANADA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. MEXICO DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE DIAGNOSTIC BIOMARKERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. EUROPE DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. FRANCE DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. GERMANY DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. ITALY DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ITALY DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. ITALY DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. SPAIN DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. UK DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 46. UK DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. UK DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. RUSSIA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. REST OF EUROPE DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC DIAGNOSTIC BIOMARKERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. ASIA-PACIFIC DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 58. CHINA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 59. CHINA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. CHINA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. JAPAN DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. INDIA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 65. INDIA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. INDIA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH KOREA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. AUSTRALIA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. THAILAND DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 78. MALAYSIA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 81. INDONESIA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA DIAGNOSTIC BIOMARKERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. LAMEA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 91. BRAZIL DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 94. SOUTH AFRICA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 97. SAUDI ARABIA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. UAE DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 99. UAE DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 100. UAE DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 103. ARGENTINA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA DIAGNOSTIC BIOMARKERS, BY PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA DIAGNOSTIC BIOMARKERS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 106. REST OF LAMEA DIAGNOSTIC BIOMARKERS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 107. QIAGEN N.V.: KEY EXECUTIVES
  • TABLE 108. QIAGEN N.V.: COMPANY SNAPSHOT
  • TABLE 109. QIAGEN N.V.: OPERATING SEGMENTS
  • TABLE 110. QIAGEN N.V.: PRODUCT PORTFOLIO
  • TABLE 111. QIAGEN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. PERKINELMER, INC.: KEY EXECUTIVES
  • TABLE 113. PERKINELMER, INC.: COMPANY SNAPSHOT
  • TABLE 114. PERKINELMER, INC.: OPERATING SEGMENTS
  • TABLE 115. PERKINELMER, INC.: PRODUCT PORTFOLIO
  • TABLE 116. PERKINELMER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. MERCK MILLIPORE: KEY EXECUTIVES
  • TABLE 118. MERCK MILLIPORE: COMPANY SNAPSHOT
  • TABLE 119. MERCK MILLIPORE: OPERATING SEGMENTS
  • TABLE 120. MERCK MILLIPORE: PRODUCT PORTFOLIO
  • TABLE 121. MERCK MILLIPORE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 123. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 124. BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 125. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 126. BIO-RAD LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. ENZO BIOCHEM, INC.: KEY EXECUTIVES
  • TABLE 128. ENZO BIOCHEM, INC.: COMPANY SNAPSHOT
  • TABLE 129. ENZO BIOCHEM, INC.: OPERATING SEGMENTS
  • TABLE 130. ENZO BIOCHEM, INC.: PRODUCT PORTFOLIO
  • TABLE 131. ENZO BIOCHEM, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. EKF DIAGNOSTICS HOLDINGS, INC.: KEY EXECUTIVES
  • TABLE 133. EKF DIAGNOSTICS HOLDINGS, INC.: COMPANY SNAPSHOT
  • TABLE 134. EKF DIAGNOSTICS HOLDINGS, INC.: OPERATING SEGMENTS
  • TABLE 135. EKF DIAGNOSTICS HOLDINGS, INC.: PRODUCT PORTFOLIO
  • TABLE 136. EKF DIAGNOSTICS HOLDINGS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. MESO SCALE DIAGNOSTICS, LLC.: KEY EXECUTIVES
  • TABLE 138. MESO SCALE DIAGNOSTICS, LLC.: COMPANY SNAPSHOT
  • TABLE 139. MESO SCALE DIAGNOSTICS, LLC.: OPERATING SEGMENTS
  • TABLE 140. MESO SCALE DIAGNOSTICS, LLC.: PRODUCT PORTFOLIO
  • TABLE 141. MESO SCALE DIAGNOSTICS, LLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. BIOSIMS TECHNOLOGIES SAS: KEY EXECUTIVES
  • TABLE 143. BIOSIMS TECHNOLOGIES SAS: COMPANY SNAPSHOT
  • TABLE 144. BIOSIMS TECHNOLOGIES SAS: OPERATING SEGMENTS
  • TABLE 145. BIOSIMS TECHNOLOGIES SAS: PRODUCT PORTFOLIO
  • TABLE 146. BIOSIMS TECHNOLOGIES SAS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. CISBIO BIOASSAYS: KEY EXECUTIVES
  • TABLE 148. CISBIO BIOASSAYS: COMPANY SNAPSHOT
  • TABLE 149. CISBIO BIOASSAYS: OPERATING SEGMENTS
  • TABLE 150. CISBIO BIOASSAYS: PRODUCT PORTFOLIO
  • TABLE 151. CISBIO BIOASSAYS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. SIGNOSIS, INC: KEY EXECUTIVES
  • TABLE 153. SIGNOSIS, INC: COMPANY SNAPSHOT
  • TABLE 154. SIGNOSIS, INC: OPERATING SEGMENTS
  • TABLE 155. SIGNOSIS, INC: PRODUCT PORTFOLIO
  • TABLE 156. SIGNOSIS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. BANYAN BIOMARKERS, INC,: KEY EXECUTIVES
  • TABLE 158. BANYAN BIOMARKERS, INC,: COMPANY SNAPSHOT
  • TABLE 159. BANYAN BIOMARKERS, INC,: OPERATING SEGMENTS
  • TABLE 160. BANYAN BIOMARKERS, INC,: PRODUCT PORTFOLIO
  • TABLE 161. BANYAN BIOMARKERS, INC,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. BIOMEDICAL CORP.: KEY EXECUTIVES
  • TABLE 163. BIOMEDICAL CORP.: COMPANY SNAPSHOT
  • TABLE 164. BIOMEDICAL CORP.: OPERATING SEGMENTS
  • TABLE 165. BIOMEDICAL CORP.: PRODUCT PORTFOLIO
  • TABLE 166. BIOMEDICAL CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL DIAGNOSTIC BIOMARKERS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL DIAGNOSTIC BIOMARKERS MARKET
  • FIGURE 3. SEGMENTATION DIAGNOSTIC BIOMARKERS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN DIAGNOSTIC BIOMARKERS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDIAGNOSTIC BIOMARKERS MARKET
  • FIGURE 11. DIAGNOSTIC BIOMARKERS MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. DIAGNOSTIC BIOMARKERS MARKET FOR SAFETY BIOMARKERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. DIAGNOSTIC BIOMARKERS MARKET FOR EFFICACY BIOMARKERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. DIAGNOSTIC BIOMARKERS MARKET FOR VALIDATION BIOMARKERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. DIAGNOSTIC BIOMARKERS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 16. DIAGNOSTIC BIOMARKERS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. DIAGNOSTIC BIOMARKERS MARKET FOR DIAGNOSTIC, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. DIAGNOSTIC BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. DIAGNOSTIC BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. DIAGNOSTIC BIOMARKERS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. DIAGNOSTIC BIOMARKERS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 22. DIAGNOSTIC BIOMARKERS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. DIAGNOSTIC BIOMARKERS MARKET FOR CANCER RESEARCH INSTITUTES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. DIAGNOSTIC BIOMARKERS MARKET FOR DIAGNOSTIC LABS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 28. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 29. COMPETITIVE DASHBOARD
  • FIGURE 30. COMPETITIVE HEATMAP: DIAGNOSTIC BIOMARKERS MARKET
  • FIGURE 31. TOP PLAYER POSITIONING, 2024
  • FIGURE 32. QIAGEN N.V.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. QIAGEN N.V.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. QIAGEN N.V.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. PERKINELMER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. PERKINELMER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. PERKINELMER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. MERCK MILLIPORE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. MERCK MILLIPORE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. MERCK MILLIPORE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. BIO-RAD LABORATORIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. ENZO BIOCHEM, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. ENZO BIOCHEM, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. ENZO BIOCHEM, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. EKF DIAGNOSTICS HOLDINGS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. EKF DIAGNOSTICS HOLDINGS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. EKF DIAGNOSTICS HOLDINGS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. MESO SCALE DIAGNOSTICS, LLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. MESO SCALE DIAGNOSTICS, LLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. MESO SCALE DIAGNOSTICS, LLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. BIOSIMS TECHNOLOGIES SAS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. BIOSIMS TECHNOLOGIES SAS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. BIOSIMS TECHNOLOGIES SAS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. CISBIO BIOASSAYS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. CISBIO BIOASSAYS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. CISBIO BIOASSAYS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. SIGNOSIS, INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. SIGNOSIS, INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. SIGNOSIS, INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 62. BANYAN BIOMARKERS, INC,: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 63. BANYAN BIOMARKERS, INC,: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 64. BANYAN BIOMARKERS, INC,: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 65. BIOMEDICAL CORP.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 66. BIOMEDICAL CORP.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 67. BIOMEDICAL CORP.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Diagnostic Biomarkers Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved